Nancy Chang - SciClone Pharmaceuticals Director
Director
Dr. Nancy T. Chang, Ph.D. is an Independent Director of SciClone Pharmaceuticals, Inc. She has served as a Director since September 2013. Since 2007, Dr. Chang has served as the President of Apex Enterprises, Inc., an investment management company with a major focus on healthcare investments. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. From 1987 to 2007, Dr. Chang served as CoFounder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson Johnson. She was also an Associate Professor at Baylor College of Medicine, and before that, she worked at the Roche Institute of Molecular Biology since 2013.
Age | 64 |
Tenure | 11 years |
Professional Marks | Ph.D |
Phone | 650 358-3456 |
Web | www.sciclone.com |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Michelle Gass | PepsiCo | 50 | |
Kuang Yang | Highway Holdings Limited | 56 | |
Shlomo Tamir | Highway Holdings Limited | 66 | |
Didier Debrosse | Compania Cervecerias Unidas | 59 | |
Cesar Conde | PepsiCo | 44 | |
Gerhard Pleuhs | Keurig Dr Pepper | 63 | |
Jorge Santos | Compania Cervecerias Unidas | N/A | |
Richard Fisher | PepsiCo | 69 | |
Pablo Lavin | Compania Cervecerias Unidas | 61 | |
Uri Oppenheimer | Highway Holdings Limited | 77 | |
Ping Wong | Highway Holdings Limited | 47 | |
Genevieve Hovde | Keurig Dr Pepper | 35 | |
Brian Geary | Highway Holdings Limited | 56 | |
Philippe Pasquet | Compania Cervecerias Unidas | 75 | |
Agnieszka Grzeszczak | PepsiCo | N/A | |
George Buckley | PepsiCo | 71 | |
Wing Leung | Highway Holdings Limited | 60 | |
Fabien Simon | Keurig Dr Pepper | 46 | |
Daniel Vasella | PepsiCo | 55 | |
David Page | PepsiCo | 61 | |
Tomasz Kietlinski | PepsiCo | N/A |
Management Performance
Return On Equity | 0.19 | |||
Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Meng, VP of Compliance and General Counsel | ||
Richard Hawkins, Independent Director | ||
Gregg Lapointe, Independent Director | ||
Hong Zhao, CEO of China Operations | ||
Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
Nancy Chang, Director | ||
Anthony Lapointe, Independent Director | ||
Lan Xie, VP of Fin. and CFO of China Operations | ||
Raymond Low, Vice President - Finance, Controller | ||
Robert King, Senior Vice President - Product Development and Supply Chain | ||
Simon Li, Independent Director | ||
Jon Saxe, Independent Chairman of the Board | ||
Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.19 | |||
Return On Asset | 0.16 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 25.82 % | |||
Current Valuation | 422 M | |||
Shares Outstanding | 52.19 M | |||
Shares Owned By Insiders | 10.03 % | |||
Shares Owned By Institutions | 79.96 % | |||
Number Of Shares Shorted | 1.21 M | |||
Price To Earning | 13.75 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards SciClone Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, SciClone Pharmaceuticals' short interest history, or implied volatility extrapolated from SciClone Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Stocks Directory Find actively traded stocks across global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |